Drug Trial Radar · NCT04179175
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
702
Actual
Start
Mar 18, 2020
Primary completion
May 26, 2023
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).
Conditions
- Hidradenitis Suppurativa
Interventions
secukinumabDrug
secukinumab 300mg every 2 weeks
secukinumabDrug
secukinumab 300mg every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) RespondersTime frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
- Incidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) RespondersTime frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
Locations
191 sites in 38 countries. Site status is shown where the registry gives one.
Northwest Arkansas Center
Rogers, Arkansas
MedDerm Associates
San Diego, California
University Clinical Trials
San Diego, California
Southern California Skin and Laser
Whittier, California
Florida Academic Centers Research and Education LLC
Coral Gables, Florida
University of MiamiHealth System
Miami, Florida
Olympian Clinical Research
Tampa, Florida
University Of South Florida
Tampa, Florida
Advanced Medical Research
Sandy Springs, Georgia
Endeavor Health
Glenview, Illinois
Dundee Dermatology
West Dundee, Illinois
Dawes Fretzin Clinical Rea Group
Indianapolis, Indiana
Tufts Medical Center
Boston, Massachusetts
Beth Israel Deaconess Med Center
Boston, Massachusetts
Minnesota Clinical Study Center
New Brighton, Minnesota
MediSearch Clinical Trials
Saint Joseph, Missouri
St Louis U Clinical Trials
St Louis, Missouri
WA Uni School Of Med
St Louis, Missouri
Skin Specialists PC
Omaha, Nebraska
Icahn School Of Med At Mount Sinai
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Wright State University
Fairborn, Ohio
UP Medical Center H System
Pittsburgh, Pennsylvania
Clinical Research Ctr of Carolinas
Charleston, South Carolina
Bellaire Dermatology Associates
Bellaire, Texas
MDRI Baylor University
Dallas, Texas
Austin Inst for Clinical Research
Pflugerville, Texas
Dr. Stephen Miller, MDPA
San Antonio, Texas
Virginia Clinical Research
Norfolk, Virginia
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Capital Federal, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Phillip, Australian Capital Territory, Australia
Novartis Investigative Site
Benowa, Queensland, Australia
Novartis Investigative Site
East Melbourne, Victoria, Australia
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.